Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Agreement Enhances Commercial Presence in Organ Transplant Centers
SAN CARLOS, Calif., Feb. 1, 2019 -- (Healthcare Sales & Marketing Network) -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, to... Diagnostics, Distribution Natera, Thermo Fisher Scientific, One Lambda, Organ Transplant Assay
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Genetics | Kidney Transplant | Kidney Transplantation | Marketing | Pharmaceuticals | Transplant Surgery | Transplants | Urology & Nephrology